|
Use of an Arginase Inhibitor to Treat Kidney Disease
Application
A method to treat cardiovascular disease in chronic kidney disease patients with an arginase inhibitor alone or in combination with arginine and/or BH4 (tetrahydrobiopterin).
Key Benefits
Potential new combination therapy for cardiovascular disease resulting from chronic kidney disease.
Market Summary
Chronic kidney disease (CKD)...
Published: 12/20/2022
Contributor(s): Loretta Reyes, Claudia Morris, Roy Sutliff
|
|
Improving Pediatric Asthma Management for Urban Families
Application
Home-based family psychoeducational intervention for low-income children with persistent asthma.
Key Benefits
Medical and psychosocial needs of patients and family members can be addressed simultaneously.
Significantly improved asthma management and caregiver stress in randomized controlled clinical trial.
Market Summary
Asthma...
Published: 12/6/2022
Contributor(s): Marianne Celano, Lisa Kobrynski, Chanda Holsey
|
|
Antisense Oligonucleotides Therapeutics Targeting Specific Tissues or Cells
Application
Antisense oligonucleotide (ASO) therapies for the treatment of rare diseases and cancer.
Key Benefits
Novel approach to ASO therapeutics that potentially improve tissue/cell targeting capabilities.
Increases the efficacy of ASOs while decrease off-target toxicity.
Potential to treat a variety of genetic diseases such as cancer,...
Published: 12/20/2022
Contributor(s): Jiahui Zhang, Khalid Salaita, Hanjoong Jo
|
|
Quinazolin-4(3H)-one Derivatives as NOX-2 Inhibitors: Composition of Matter, Methods of Preparation and Their Use
Application
Quinazolin-4(3H)-one derivatives as selective NOX-2 inhibitors to prevent oxidative damage.
Key Benefits
Small molecule NOX-2 specific inhibitor.
Prevents excessive reactive oxygen species (ROS) generation rather than removing them.
Selective NOX-2 inhibition offers significant advantages to development of an effective therapy against...
Published: 12/6/2022
Contributor(s): Thota Ganesh, Radhika Amaradhi, Jacek Zielonka
|
|
Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
Application
A small molecule compound to treat Malignant Glioblastoma multiforme.
Key Benefits
Dual inhibition of NQO1 and GSTP1 induces cell death in glioblastoma cells.
Inhibition of NQO1 and GSTP1 by MNPC suppresses tumor growth and elongates the life span of the animals with GBM.
Market Summary
Approximately 30% of patients diagnosed...
Published: 12/20/2022
Contributor(s): Keqiang Ye
|
|
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
Application
Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.
Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Coronavirus (COVID-19) is an infectious...
Published: 10/28/2022
Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
|
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type...
Published: 12/6/2022
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
|
Use of MAST1 Inhibitor in Treatment of Platinum-Based Chemotherapy
Application
A combination therapy product for treatment of patients having cisplatin-resistant cancer.
Key Benefits
Identified the use of MAST1 inhibitors (such as lestaurtinib) to target cisplatin-resistant cancer.
Lestaurtinib sensitized cells to cisplatin treatment the most using a concentration that attenuates cell viability by less...
Published: 12/6/2022
Contributor(s): Sumin Kang, Jing Chen, Lingtao Jin
|
|
Tumor Specific CD8 T Cell TCR Sequences of HPV-Positive Head and Neck Tumors
Application
HPV-specific CD8 TCR sequences for the treatment of HPV-positive head and neck cancer by adoptive cell therapy.
Key Benefits
HPV tumor antigen set is specific for HPV-positive head and neck cancer.
Targeting of ‘non-classical’ HPV antigens E2 and E5.
Potential to synergize and complement HPV E6/7-specific TCR therapies...
Published: 10/28/2022
Contributor(s): Rafi Ahmed, Christiane Eberhardt, Andreas Wieland
|
|
CBCT-Guided Adaptive Photon and Proton Radiotherapy
Application
Generating synthetic MRI images from CBCT images with deep learning.
Key Benefits
Generate high contrast MRI images from cone-beam CT images.
High quality, high contrast images to enable precise radiation treatment.
Market Summary
Radiation therapy (RT) is one of the most common treatment modalities for cancer and is used...
Published: 9/29/2022
Contributor(s): Xiaofeng Yang, Yang Lei, Tian Liu, Jun Zhou
|